Understanding COVID-19 immune response
While most COVID-19 patients are asymptomatic or display mild symptoms, some patients develop severe clinical symptoms. The pathogenic basis for this difference in disease severity among patients is poorly understood. Developing a better understanding of immune response across patient populations is crucial to understanding these differences, and to the development of future vaccines capable of targeting novel COVID-19 variants.
This webinar will present cutting edge research and provide insights from the intersection between three areas of intense current focus – COVID-19 clinical research, single cell analysis and the measurement of T-cell response.
Attendees will leave with new approaches and ideas for achieving in-depth characterization of the CD8+ T-cell-mediated response to COVID-19 infection, which will support (1) the development of better molecular and targeted therapies, and (2) the development of better vaccination strategies.
This webinar consists of 2 presentations, followed by a Q&A session.
Talk 1: Dissecting CD8+ T-cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping
Felix Schreibing, MD, Postdoctoral Fellow, Institute of Experimental Medicine and Systems Biology. University Hospital RWTH Aachen
Talk 2: dCODE Dextramer® – Unravelling the specificity of T-cell immunity
Matilda Felicia Weywadt, Ph.D., Product Manager, Immudex
– Felix Schreibing, MD, Postdoctoral Fellow, Institute of Experimental Medicine and Systems Biology. University Hospital RWTH Aachen
– Matilda Felicia Weywadt, Ph.D., Product Manager, Immudex
– Monica Hannini, Ph.D. Fellow, Institute of Experimental Medicine and Systems Biology, University Hospital RWTH Aachen
This webinar has been made possible with the kind support of our partner, Immudex. To find out more about the dCODE Dextramer® technology, visit the Immudex website.